SCHEMBL388722

SCHEMBL388722

O=C1C[CH]C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6346250 0.88
SCHEMBL7072753 0.79
SCHEMBL290556 0.73
SCHEMBL489453 0.69
SCHEMBL72417 0.69
SCHEMBL6101053 0.67
SCHEMBL11376830 0.67 TRIM24 (0.31)
SCHEMBL52489 0.67
SCHEMBL11376825 0.67 TRIM24 (0.31)
Iodide SCHEMBL11339547 0.64

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 621 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4399209-A1 NEW QUINOLINE DERIVATIVES Elanco Animal Health GmbH (DE) 2024-07-17 EP claimed
CN-118026938-A Pyrazolone ester compound and electrochemical synthesis method thereof 江西本草天工科技有限责任公司 2024-05-14 CN claimed
CN-117957223-A Quinoline derivatives 礼蓝动物保健有限公司 2024-04-30 CN claimed
WO-2023036821-A1 NEW QUINOLINE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2023-03-16 WO claimed
EP-4148052-A1 NEW QUINOLINE DERIVATIVES Bayer Animal Health GmbH (DE) 2023-03-15 EP claimed
CN-106928219-B Nitrogen-containing fused heterocyclic compound, preparation method, intermediate, composition and application 上海医药集团股份有限公司 2021-08-20 CN claimed
US-10195178-B2 GPR40 agonists in anti-diabetic drug combinations JANSSEN PHARMACEUTICA NV (BE) 2019-02-05 US claimed
US-10131648-B2 Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes JANSSEN PHARMACEUTICA NV (BE) 2018-11-20 US claimed
US-20170362196-A1 SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES JANSSEN PHARMACEUTICA NV (BE) 2017-12-21 US claimed
WO-2017180457-A1 GPR40 AGONISTS IN ANTI-DIABETIC DRUG COMBINATIONS JANSSEN PHARMACEUTICA NV (BE) 2017-10-19 WO claimed
US-7164019-B2 Such as cyclopentanecarboxylic acid {(S)-1-phenyl-3-[5-(pyridine-3-carbonyl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-propyl}-amide; antagonists of chemokine receptors, useful for treating/preventing human immunodeficiency virus infection, AIDS or ARC ROCHE PALO ALTO LLC (US) 2007-01-16 US claimed
US-20060014767-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2006-01-19 US claimed
WO-2005121145-A2 OCTAHYDRO-PYRROLO[3,4-C] DERIVATIVES AND THEIR USE AS ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2005-12-22 WO claimed
US-20040063714-A1 Triazolo-pyridazine derivatives as ligands for GABA receptors CARLING WILLIAM ROBERT (GB) 2004-04-01 US claimed
CN-1110498-C Triazolo-pyridazine derivatives as ligands for GABA receptors MERCK SHARP & DOHME (GB) 2003-06-04 CN claimed
CN-1288465-A Triazolo-pyridazine derivatives as ligands for GABA receptors MERCK SHARP & DOHME (GB) 2001-03-21 CN claimed
EP-1049696-A1 TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP &amp; DOHME LTD. (GB) 2000-11-08 EP claimed
US-6077859-A Pyrazoles PFIZER INC. (US) 2000-06-20 US claimed
EP-0959071-A1 1-Aryl-4-cycloalk(en)ylpyrazoles as antiparasitic agents PFIZER INC. (US) 1999-11-24 EP claimed
WO-1999037644-A1 TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LIMITED (GB) 1999-07-29 WO claimed